公司简介
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strat...
关联新闻
- Helus Pharma's psychedelic depression drug succeeds in late-stage study
Helus Pharma said on Monday its experimental psychedelic drug showed statistically significant improvement in depression symptoms compared with placebo in a late-stage trial in patients with ma...